The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Viking Therapeutics Appoints First Chief Commercial Officer
PUBLIC · VKTXMay 31, 2026•17 days ago
Position
Chief Commercial Officer
Company
Viking Therapeutics
Unknown Unknown
San DiegoBiotechnology
Description
Viking Therapeutics has appointed its first Chief Commercial Officer to prepare for the potential commercialization of its VK2735 obesity drug candidates. This appointment comes as the company pushes the VK2735 program into late-stage development, including a Phase III trial.
Company Information
Company
Viking Therapeutics
Location
9920 Pacific Heights Blvd,, Suite 350
San Diego, California, United States
About
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel 1st-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with two programs currently in clinical trials.
Viking's clinical programs include VK2735, a novel dual agonist of the GLP-1 and GIP receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 2 trial.
San DiegoBiotechnology